使用寡合胆酸的仿制GLP-1A的设计,以利用载体介导内细胞形成,用于口服输送
Seho Kweon1,2, Jun-Hyuck Lee3, Seong-Bin Yang3
1Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea.
研究人员通过将其与脱氧醇酸 (DOCA) 寡合体结合,开发出一种新的仿制葡萄糖类-1激动剂 (GLP-1A). 这种增强的GLP-1A表现出改善的口服生物可用性和强大的低血糖作用,为糖尿病治疗提供了一个有前途的新策略.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药物运输 药物运输 药物运输
背景情况:
- 类似葡萄糖类-1激动剂 (GLP-1A) 对糖尿病有效,但由于其分子性质,其口服生物利用性较差.
- 准肠道输送体,如尾依赖的胆酸输送体 (ASBT),可以提高GLP-1A的细胞透性.
研究的目的:
- 通过将其与寡合脱氧醇酸 (DOCA) 结合,开发一种仿制GLP-1A,以改善口服输送.
- 为了评估新奇化学物质GLP-1A的结合亲和力,细胞透性,生物可用性和治疗疗效.
主要方法:
- 在基分子对接和动力学模拟中评估DOCA-ASBT相互作用.
- 合成化学GLP-1A结合的寡合DOCA (mD-G1A,bD-G1A,tD-G1A) 的合成.
- 实验室和体内研究包括Caco-2的透性,胰岛素透性作用,大鼠口服吸收,糖尿病小鼠的低血糖作用.
主要成果:
- 泰特拉多卡 (TetraDOCA) 显示出与ASBT的高结合 afinity.
- 化学GLP-1A-DOCA保留了胰岛素的作用.
- bD-G1A和tD-G1A在老鼠 (7.58%和8.63%) 中表现出增强的Caco-2透性和改善的口服生物可用性.
- 在糖尿病小鼠中,tD-G1A显著降低了葡萄糖水平.
结论:
- 寡合性DOCA有效地与GLP-1A结合,产生一种具有潜在的口服输送的化学化合物.
- 开发的仿制GLP-1A表现出有前途的受体激素活性和增强的口服生物可用性.
- 寡合体DOCA作为口服GLP-1A输送的有效载体,在糖尿病管理中提供了潜在的进步.
更多相关视频
09:34Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Receptor-mediated Endocytosis
Drug Delivery: Enteral Route
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Lipid Digestion
